Loading
A phase 2 trial of FOLFOX in colorectal cancer, run by Alethia Biotherapeutics, now recruiting.
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis is a phase 2 interventional study registered as NCT06225843 by Alethia Biotherapeutics, with 17 participants planned, started 2024-02-15 and due to reach its primary completion in 2026-03. Interventions recorded: Sotevtamab, FOLFOX. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/